• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension.

作者信息

Nazer Babak, Humphreys Benjamin D, Moslehi Javid

机构信息

Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.

出版信息

Circulation. 2011 Oct 11;124(15):1687-91. doi: 10.1161/CIRCULATIONAHA.110.992230.

DOI:10.1161/CIRCULATIONAHA.110.992230
PMID:21986775
Abstract
摘要

相似文献

1
Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension.新型血管生成抑制剂治疗癌症对心血管系统的影响：聚焦于高血压。
Circulation. 2011 Oct 11;124(15):1687-91. doi: 10.1161/CIRCULATIONAHA.110.992230.
2
Bevacizumab: overview of the literature.贝伐珠单抗：文献综述。
Expert Rev Anticancer Ther. 2012 May;12(5):567-80. doi: 10.1586/era.12.13.
3
Hypertension associated with angiogoenesis inhibitors: what do oncologists really do in daily routine? A small survey.与血管生成抑制剂相关的高血压：肿瘤学家在日常工作中实际做些什么？一项小型调查。
J Clin Hypertens (Greenwich). 2011 Nov;13(11):863. doi: 10.1111/j.1751-7176.2011.00526.x. Epub 2011 Aug 24.
4
Cardiac testing to manage cardiovascular risk in cancer patients.对癌症患者进行心脏检测以管理心血管风险。
Semin Oncol. 2013 Apr;40(2):147-55. doi: 10.1053/j.seminoncol.2013.01.003.
5
Systemic administration of bevacizumab increases the risk of cardiovascular events in patients with metastatic cancer.贝伐单抗的全身给药会增加转移性癌症患者发生心血管事件的风险。
Int J Cardiol. 2012 Feb 9;154(3):341-4. doi: 10.1016/j.ijcard.2011.10.115. Epub 2011 Nov 9.
6
Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature.抗血管生成药物治疗复发性胶质母细胞瘤患者的高血压作为生物标志物：单中心经验和文献综述。
Anticancer Drugs. 2013 Jan;24(1):90-7. doi: 10.1097/CAD.0b013e32835aa5fd.
7
Retrobulbar optic neuritis in a bevacizumab-treated patient with metastatic breast cancer.一名接受贝伐单抗治疗的转移性乳腺癌患者发生球后视神经炎。
Breast J. 2012 Sep;18(5):502-3. doi: 10.1111/j.1524-4741.2012.01293.x. Epub 2012 Aug 15.
8
[Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity].[血管生成抑制剂疗法：聚焦高血压与肾毒性]
Bull Cancer. 2007 Nov;94(11):981-6.
9
Bevacizumab recommendation highlights difficulties.贝伐单抗的推荐凸显了困难。
Cancer. 2011 Nov 15;117(22):5025. doi: 10.1002/cncr.26642.
10
FDA panel votes to pull Avastin in breast cancer, again.美国食品药品监督管理局专家小组再次投票决定撤销阿瓦斯汀用于治疗乳腺癌的许可。
Nat Biotechnol. 2011 Aug 5;29(8):676. doi: 10.1038/nbt0811-676c.

引用本文的文献

1
Navigating the Complexities of Cancer Treatment-Induced Hypertension.应对癌症治疗引发的高血压的复杂性
J Cardiovasc Dev Dis. 2025 Jun 19;12(6):235. doi: 10.3390/jcdd12060235.
2
From Bench to Bedside: Translational Approaches to Cardiotoxicity in Breast Cancer, Lung Cancer, and Lymphoma Therapies.从 bench 到 bedside：乳腺癌、肺癌和淋巴瘤治疗中心脏毒性的转化研究方法
Cancers (Basel). 2025 Mar 21;17(7):1059. doi: 10.3390/cancers17071059.
3
Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision).
《中国高血压防治指南（2024年修订版）》
J Geriatr Cardiol. 2025 Jan 28;22(1):1-149. doi: 10.26599/1671-5411.2025.01.008.
4
Vascular endothelial growth factor-tyrosine kinase inhibitors: Novel mechanisms, predictors of hypertension and management strategies.血管内皮生长因子-酪氨酸激酶抑制剂：新机制、高血压预测因素及管理策略
Am Heart J Plus. 2022 May 26;17:100144. doi: 10.1016/j.ahjo.2022.100144. eCollection 2022 May.
5
Novel insights into cardiovascular toxicity of cancer targeted and immune therapies: Beyond ischemia with non-obstructive coronary arteries (INOCA).癌症靶向治疗和免疫治疗心血管毒性的新见解：超越非阻塞性冠状动脉缺血（INOCA）。
Am Heart J Plus. 2024 Mar 1;40:100374. doi: 10.1016/j.ahjo.2024.100374. eCollection 2024 Apr.
6
Cardiovascular disease and lung cancer.心血管疾病和肺癌。
Front Oncol. 2024 Feb 12;14:1258991. doi: 10.3389/fonc.2024.1258991. eCollection 2024.
7
Risk of cardiovascular toxicity with combination of immune-checkpoint inhibitors and angiogenesis inhibitors: a meta-analysis.免疫检查点抑制剂与血管生成抑制剂联合使用时心血管毒性的风险：一项荟萃分析。
Front Cardiovasc Med. 2024 Feb 2;11:1309100. doi: 10.3389/fcvm.2024.1309100. eCollection 2024.
8
Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension-Mechanisms and Mitigation.已确立和新兴的癌症疗法与心血管系统：聚焦高血压——机制与缓解。
Hypertension. 2023 Apr;80(4):685-710. doi: 10.1161/HYPERTENSIONAHA.122.17947. Epub 2023 Feb 9.
9
Cancer Immunotherapy Beyond Checkpoint Blockade: State-of-the-Art Review.超越检查点阻断的癌症免疫疗法：最新综述。
JACC CardioOncol. 2022 Dec 20;4(5):563-578. doi: 10.1016/j.jaccao.2022.11.006. eCollection 2022 Dec.
10
Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer.心肿瘤代谢学：心血管疾病和癌症中的代谢重塑。
Nat Rev Cardiol. 2022 Jun;19(6):414-425. doi: 10.1038/s41569-022-00698-6. Epub 2022 Apr 19.